Thursday, 12 November 2026European Markets

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows

The euro has gained 14% against the US dollar in 2025, while the British pound climbed 7%, as the greenback fell to its lowest level since 2022. The dollar's weakness stems from uncertainty ahead of Jerome Powell's June 2026 Federal Reserve departure and shifting investor sentiment toward European currencies.

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro traded 14% higher against the US dollar in 2025, marking the greenback's steepest decline since 2022. The British pound gained 7% over the same period, reflecting a broad shift away from dollar-denominated assets.

Market uncertainty around the June 2026 Federal Reserve chair transition from Jerome Powell has weakened dollar confidence. Geopolitical developments, including progress on Iran-US nuclear negotiations, have accelerated the currency rotation.

European investors face new opportunities as dollar weakness makes US assets cheaper. American stocks, bonds, and real estate now cost 14% less in euro terms than at the start of 2025. European companies with US revenue streams see higher euro-equivalent earnings on repatriation.

The shift benefits European exporters to the United States. German manufacturers and French luxury brands gain pricing power as their products become more competitive against US-produced alternatives. Tourism sectors across Spain, Italy, and Greece expect increased American visitor spending.

Currency analysts warn the dollar's decline may reach limits soon. Jordan Rochester at Mizuho Bank forecasts potential GBP reversal below $1.30 as the UK Budget and Fed leadership change approach. Simon Phillips at No1 Currency noted pressure on sterling despite recent gains.

European bond markets have strengthened alongside currency gains. The euro's rise makes European government debt more attractive to international investors seeking alternatives to US Treasuries. UK gilt auctions drew record demand, with £69 billion in bids for £4.25 billion in inflation-linked bonds.

Strategic investors should consider US dollar exposure while valuations favor euro-based buyers. Technology stocks trading on US exchanges offer entry points 14% below year-start euro prices. Real estate investment trusts and corporate bonds present similar opportunities.

The currency shift also carries risks. A sudden dollar rebound would reduce gains on US holdings. European Central Bank policy decisions and eurozone economic data will determine whether the euro maintains its strength through year-end.

Market sentiment currently favors non-dollar currencies, but analysts caution against assuming permanent trends. Fed policy clarity following the 2026 chair transition could restore dollar demand.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com